Format

Send to

Choose Destination
Oncol Lett. 2019 Aug;18(2):1388-1394. doi: 10.3892/ol.2019.10437. Epub 2019 Jun 5.

Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy.

Author information

1
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama 350-8550, Japan.
2
Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa 761-0793, Japan.
3
Division of Translation Research, Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama 350-1241, Japan.
4
Department of Surgery, Teikyo University Chiba Medical Center, Ichihara, Chiba 299-0111, Japan.
5
Cancer Treatment Center, Kochi Medical School Hospital, Nankoku, Kochi 783-8505, Japan.
6
Department of Surgery, Iwakuni Clinical Center, Iwakuni, Yamaguchi 740-8510, Japan.
7
Department of Pharmacy, Kanazawa Red Cross Hospital, Kanazawa, Ishikawa 921-8162, Japan.
8
Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Tokyo 114-8431, Japan.

Abstract

Approximately 30% patients with stage III colon cancer (CC) develop local recurrence and/or distant metastasis, even if postoperative adjuvant chemotherapy with oxaliplatin plus 5-fluorouracil and leucovorin (5-FU/LV) has been completed. In the present study, molecular analysis was performed to identify molecular markers of tumor recurrence in patients with stage III CC receiving oxaliplatin-based adjuvant chemotherapy. The FACOS study was conducted as a phase II study to evaluate the safety and efficacy of oxaliplatin-based treatment for stage III CC patients. Of the 132 CC patients enrolled in the present study, gene expression analysis using a microarray was conducted in 51 patients. Of these 51 patients, 6 developed recurrence within 5 years. The topmost 5% genes that showed differential expressions between cases that developed/did not develop recurrence were selected, and a set of predictive molecular markers for recurrence was identified. Of the 34,694 genes in the microarray, 1,734 genes were extracted as topmost 5% genes showing differential expressions between cases with and without recurrence. Among these, 10 genes, includingADH1A, ADH1C, CA12, CHP2, HMGCS2, SNAR-A1, TPI1, MS4A12, PLA2G10 and PTPRO, were identified as markers that could clearly divide patients with and without recurrence. Although several prediction models of tumor recurrence have been reported for CC, the set of 10 genes that the present study identified may be useful to predict the risk of recurrence in stage III CC patients receiving oxaliplatin-based adjuvant chemotherapy. Based on these results, high-risk patients with CC should be carefully observed to detect tumor recurrence during the follow-up period.

KEYWORDS:

colon cancer; molecular marker; oxaliplatin

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center